ライフサイエンスコーパス: adverse cardiac event

1 mortality) into a composite end point (major adverse cardiac events).

2 s, 2183 (23.9%) patients experienced a major adverse cardiac event.

3 se events, serious adverse events, and major adverse cardiac event.

4 The primary safety end point was a major adverse cardiac event.

5 cond, we analyzed the association with major adverse cardiac event.

6 with a 1.8-fold increase in risk of a major adverse cardiac event.

7 th venous thromboembolism but not with major adverse cardiac events.

8 with respect to the rate of subsequent major adverse cardiac events.

9 dependent prognostic imaging marker of major adverse cardiac events.

10 y intervention in reducing the risk of major adverse cardiac events.

11 inary in-stent restenosis and 12-month major adverse cardiac events.

12 , target lesion revascularization, and major adverse cardiac events.

13 s with Fabry disease who are at high risk of adverse cardiac events.

14 th negative test results go on to experience adverse cardiac events.

15 owed for 30 days for the occurrence of major adverse cardiac events.

16 improved prediction of 1-year death or major adverse cardiac events.

17 diac troponin T with the occurrence of major adverse cardiac events.

18 ssociated with increased risk of in-hospital adverse cardiac events.

19 y periprocedural mortality and rate of major adverse cardiac events.

20 int of the study was the occurrence of major adverse cardiac events.

21 ntly associated with the occurrence of major adverse cardiac events.

22 CMR was significantly associated with major adverse cardiac events.

23 int of the study was the occurrence of major adverse cardiac events.

24 clinical risk score for prediction of major adverse cardiac events.

25 independent predictor of mortality and major adverse cardiac events.

26 e long-term risk of all-cause death or major adverse cardiac events.

27 was noninferior to FFR with respect to major adverse cardiac events.

28 clinical events committee adjudicated major adverse cardiac events.

29 c vein-graft harvesting in the risk of major adverse cardiac events.

30 rse event but was associated with cumulative adverse cardiac events.

31 DL-P subfractions and time to death or major adverse cardiac events.

32 tted to the early diagnosis and treatment of adverse cardiac events.

33 anges in LV volumes, infarct size, and major adverse cardiac events.

34 iomyopathy/dysplasia and a high incidence of adverse cardiac events.

35 ng CA, there was a temporal decline in major adverse cardiac events (0.98 [0.97-0.99], P<0.001) and m

36 There was no difference in major adverse cardiac events (1.8% versus 2.3%; P=0.75) at 30

37 % versus 19.12%; P=0.078) and 12-month major adverse cardiac events (10.29% versus 19.12%; P=0.213) w

38 [3.4%] vs 29 of 365 [7.9%]; P = .007), major adverse cardiac events (15 of 382 [3.9%] vs 30 of 365 [8

39 te group, and 4% in the vilanterol group) or adverse cardiac events (17% in the placebo group, 18% in

40 606 patients/y) 145 CVEs (3.15%/y), 98 major adverse cardiac event (2.13%/y), and 57 cardiovascular d

41 tality (8 [7.7%] versus 12 [1.9%]) and major adverse cardiac events (21 [20.2%] versus 31 [4.9%]) rat

42 follow-up, there was no difference for major adverse cardiac events (25.3 versus 25.4%; P=0.683); all

43 confidence interval: 0.46 to 1.66) and major adverse cardiac events (4.8% vs. 5.5%; adjusted hazard r

44 oing stress-CMR showed a lower rate of major adverse cardiac events (5% versus 10%; P<0.010) and cost

45 ciated with a reduction in the risk of major adverse cardiac events (6.5% versus 10.3%; odds ratio, 0

46 ality (40.5% vs. 18.7%; p <0.001), and major adverse cardiac events (63.6% vs. 23.5%; p <0.001).

47 tality 50.0% vs. 19.6%; p = 0.001, and major adverse cardiac events 70.0% vs. 18.9%; p < 0.001).

48 use death, all-cause readmissions, and major adverse cardiac events (a composite of all-cause death o

49 The primary end point was major adverse cardiac events, a composite of cardiac death, my

50 Primary end point was the rate of major adverse cardiac events, a composite of cardiac death, ta

51 terms of major adverse cardiac events (major adverse cardiac events, a composite of death, myocardial

52 coprimary end points were the rates of major adverse cardiac events--a composite of death, myocardial

53 mary end point was the occurrence of a major adverse cardiac event: a composite of death, reinfarctio

54 s associated with an increased risk of major adverse cardiac events across all bleeding risk groups.

55 ssociated with a higher 2-year risk of major adverse cardiac events (adjusted hazard ratio, 2.34; 95%

56 n between HPR and SVG PCI in regard to major adverse cardiac events (adjusted Pinteraction=0.99).

57 Patients were evaluated for adverse cardiac events after cardiac magnetic resonance

58 There were no major adverse cardiac events after discharge in either group.

59 total mortality or hospitalization for major adverse cardiac events (aHR: 0.30; 95% CI: 0.12 to 0.78)

60 total mortality or hospitalization for major adverse cardiac events (aHR: 2.02; 95% CI: 1.32 to 3.07)

61 rs to determine medication history and major adverse cardiac events: all-cause mortality, nonfatal my

62 ate, an abnormal MPI failed to predict major adverse cardiac events, although it was associated with

63 edural success but were not related to major adverse cardiac event among patients undergoing CTO-PCIs

64 he incremental risk of noncardiac surgery on adverse cardiac events among post-stent patients is high

65 </=1, nitrite reduced infarct size and major adverse cardiac event and improved myocardial salvage in

66 0001) with low negative event rates of major adverse cardiac events and cardiac death (0.6% and 0.4%,

67 g hospitalization and 1-year outcomes (major adverse cardiac events and complications), respectively.

68 erienced significantly higher rates of major adverse cardiac events and coronary revascularization th

69 PP-SES had higher rates of major adverse cardiac events and definite stent thrombosis.

70 increased short-term and long-term risk for adverse cardiac events and mortality.

71 PCI significantly reduced the rate of major adverse cardiac events and new congestive heart failure

72 Major adverse cardiac events and target lesion failure through

73 composite outcome of 1-year mortality, major adverse cardiac events and/or other major complications

74 ks of 30-day all-cause readmissions or major adverse cardiac events, and 1-year mortality, all-cause

75 evaluated mortality, 7 (30%) evaluated major adverse cardiac events, and 2 (9%) evaluated angiographi

76 ailure Questionnaire, 6-min walk test, major adverse cardiac events, and immune biomarkers.

77 CMR has a high negative predictive value for adverse cardiac events, and the absence of inducible per

78 on myocardial infarction patients with major adverse cardiac events as compared with those without (2

79 time to recurrent nonfatal HF-related major adverse cardiac events as the primary efficacy end point

80 Importantly, the risk for major adverse cardiac events associated with FFR/CFVR discorda

81 (P=0.05) and reduction in [corrected] major adverse cardiac event at 1 year (2.6% versus 15.8%; P=0.

82 ear (HR, 1.24; 95% CI, 1.14-1.36), and major adverse cardiac events at 1 year (HR, 1.21; 95% CI, 1.12

83 Major adverse cardiac events at 1 year occurred in 24 patients

84 Major adverse cardiac events at 1 year were higher with the MG

85 The primary endpoint was major adverse cardiac events at 1 year, and the data for the 5

86 er in postoperative NT-proBNP release, major adverse cardiac events at 1 year, or delirium.

87 mbus was independently associated with major adverse cardiac events at 1-year follow-up.

88 ently associated with the incidence of major adverse cardiac events at 12 months (hazard ratio, 2.73;

89 n strategy with respect to the rate of major adverse cardiac events at 12 months.

90 Major adverse cardiac events at 3 years were significantly low

91 6 weeks and 1.8 percentage points for major adverse cardiac events at 9 months.

92 s abciximab and found similar rates of major adverse cardiac events at 90 days with significantly les

93 er volume was associated with improved major adverse cardiac events at every threshold, regardless of

94 mine whether the 1-year differences in major adverse cardiac event between a stent eluting biolimus f

95 No difference was observed in major adverse cardiac events between sexes and ED strategies (

96 The 10-year incidence of major adverse cardiac event (BP-SES 47.7% versus PP-EES 46.0%

97 There was no difference in 30-day major adverse cardiac events, but at 12 months the HSLD group

98 noncardiac surgery contribute to the risk of adverse cardiac events, but the relative contributions o

99 mortality, all-cause readmissions, or major adverse cardiac events, but these were attenuated after

100 th no differential treatment effect on major adverse cardiac events by baseline heart failure (HF) st

101 ry disease) improved discrimination of major adverse cardiac events (C statistic, 0.81-0.86; P=0.04;

102 endpoint was randomized lesion-related major adverse cardiac events (cardiac death, MI, unstable angi

103 with increased risk for postdischarge major adverse cardiac events (cardiac death, myocardial infarc

104 The primary end point was in-hospital major adverse cardiac events (cardiac death, myocardial infarc

105 Major adverse cardiac events (cardiac death, nonfatal MI, unpl

106 The primary outcome was major adverse cardiac events (cardiac death, recurrent myocard

107 erformed to document the occurrence of major adverse cardiac events: cardiac death, myocardial infarc

108 medical history and the occurrence of major adverse cardiac events (cardiovascular death, myocardial

109 target lesion revascularization), and major adverse cardiac events (combination of all-cause death,

110 n contrast, PostC alone did not reduce major adverse cardiac events compared with controls (14.1% ver

111 d EQW effects on all-cause death, each major adverse cardiac event component, first HHF, and repeat H

112 Endpoints were major adverse cardiac events (composite of death, reinfarction

113 mortality, myocardial infarction, and major adverse cardiac events (comprising mortality, myocardial

114 Major adverse cardiac events consisting of cardiac death, rein

115 Major adverse cardiac events could be predicted using a seven-

116 Estimated 10-year rate of major adverse cardiac events (death, heart failure, myocardial

117 entations had an independent effect on major adverse cardiac events (death, MI, and re-target lesion

118 x length of stay, early discharge, and major adverse cardiac events (death, myocardial infarction, or

119 y outcome was 1-year composite rate of major adverse cardiac events (death, myocardial infarction, or

120 The primary end point was 1-year major adverse cardiac events (death, myocardial infarction, or

121 Postoperative adverse cardiac events decrease as the time from stent p

122 rimary outcome measure was in-hospital major adverse cardiac events defined as a composite of all-cau

123 The primary end point was major adverse cardiac events defined as all-cause mortality, h

124 , cumulative effective radiation dose, major adverse cardiac events, defined as a composite end point

125 The primary end point of interest was major adverse cardiac events, defined as the composite of card

126 ssful procedure without device-related major adverse cardiac events during 6 months.

127 The rate of major adverse cardiac events during a median follow-up of 12.1

128 ationic protein serum levels predicted major adverse cardiac events during follow-up (odds ratio =1.0

129 death, myocardial infarction (MI), and major adverse cardiac events during the follow-up period (medi

130 linked to approximately 19% incidence of an adverse cardiac event (e.g., heart failure, arrhythmia,

131 such as recurrent nonfatal HF-related major adverse cardiac events, enables generation of clinically

132 EL trial, the 4-year primary composite major adverse cardiac event end point of death, myocardial inf

133 The 4-year rate of the primary major adverse cardiac event end point of death, stroke, or myo

134 Adverse cardiac events followed surgery in 531 (5.7%) of

135 resulted in a significant decrease of major adverse cardiac events for up to 2 years after the index

136 BG and 2255 PCI patients, Kaplan-Meier major adverse cardiac event-free survival curves demonstrated

137 herapy as a more powerful predictor of major adverse cardiac event-free survival than choice of thera

138 adherent patients, CABG affords better major adverse cardiac event-free survival.

139 an FFR-based strategy with respect to major adverse cardiac events has not been established.

140 1.524 [95% CI, 1.021-2.274], P=0.039), major adverse cardiac event (hazard ratio, 1.917 [95% CI, 1.20

141 as a powerful incremental predictor of major adverse cardiac events (hazard ratio, 0.80 [95% confiden

142 % higher hazard for all-cause death or major adverse cardiac events (hazard ratio, 1.06; 95% CI, 1.03

143 ndiabetic patients had higher risks of major adverse cardiac events (hazard ratio, 1.25; 95% confiden

144 tly associated with all-cause death or major adverse cardiac events (hazard ratio, 2.88; 95% CI, 1.59

145 a significant independent predictor of major adverse cardiac events (hazard ratio, 4.41 [confidence i

146 demonstrated a strong association with major adverse cardiac events (hazard ratio=14.66; P<0.0001) wi

147 cally significant predictor of time to major adverse cardiac events (hazard-ratio, 3.36; 95% confiden

148 ciated with higher incidence of 1-year major adverse cardiac event (hazards ratio=2.2; P=0.02).

149 One-year major adverse cardiac events, heart failure hospitalizations,

150 8; P=0.004), and composite adjudicated major adverse cardiac events (ie, cardiac death, myocardial in

151 ity, cardiac events, and the composite major adverse cardiac events (ie, death, acute myocardial infa

152 trend toward higher unadjusted 1-year major adverse cardiac events in AA (12.0% versus 8.0%; P=0.06)

153 the risk for CCM in children and adults, and adverse cardiac events in adults.

154 not associated with increased risk of major adverse cardiac events in both HBR and non-HBR patients,

155 dependently associated with 30-day death and adverse cardiac events in patients 65 years or older und

156 <39%) on postoperative 30-day mortality and adverse cardiac events in patients 65 years or older und

157 hemorrhage, MI, stent thrombosis, and major adverse cardiac events in patients randomized to prolong

158 ngs on positron emission tomography (PET) to adverse cardiac events in patients referred for evaluati

159 nostic value of stress CMR for prediction of adverse cardiac events in patients with known or suspect

160 h results from carbamylation, predicts major adverse cardiac events in patients with normal renal fun

161 Risks of SCAD recurrence and major adverse cardiac events in the long term emphasize the ne

162 Major adverse cardiac events included death, myocardial infarc

163 Independent predictors of major adverse cardiac events included renal disease, prior myo

164 evels in blood predict future risk for major adverse cardiac events including myocardial infarction,

165 No herpes zoster cases or major adverse cardiac events including thromboembolic events o

166 We assessed major adverse cardiac events, including cardiac death, myocard

167 Major adverse cardiac events, including cardiac death, nonfata

168 The primary outcome was a composite of major adverse cardiac events, including death from any cause,

169 entified a subgroup with a very low risk for adverse cardiac events, including ventricular arrhythmia

170 Mortality and major adverse cardiac events increase as operator volumes decr

171 ath or nonfatal myocardial infarction (major adverse cardiac events) incremental to clinical risk mod

172 olic fatty liver disease and predicted major adverse cardiac events independently of nonalcoholic fat

173 s associated with an increased risk of major adverse cardiac events irrespective of the underlying bl

174 ntification of imaging findings that predict adverse cardiac events is needed to enable identificatio

175 tween operator and site experience and major adverse cardiac event (likelihood ratio test=19.12, df=1

176 Recently, major adverse cardiac event (MACE) and mortality risk calculat

177 his study recorded the occurrence of a major adverse cardiac event (MACE) assessed as the composite o

178 hospitalization (primary outcome) or a major adverse cardiac event (MACE) or death within 30 days (se

179 P-4 inhibitor alogliptin to placebo on major adverse cardiac event (MACE) rates in patients with type

180 follow-up after the index ACS, time to major adverse cardiac event (MACE) was investigated using Cox

181 The primary endpoint was a major adverse cardiac event (MACE) within 30 days.

182 The primary endpoint was major adverse cardiac event (MACE) within 30 days.

183 ation were followed for instances of a major adverse cardiac event (MACE), such as a myocardial infar

184 cardiac tumour formation on MRI, or a major adverse cardiac event (MACE; composite of death and hosp

185 sessed the association between sex and major adverse cardiac events (MACE) (cardiac death, myocardial

186 primary endpoint was the composite of major adverse cardiac events (MACE) (cardiovascular death, myo

187 Endpoints were adjudicated major adverse cardiac events (MACE) (death, myocardial infarct

188 idence interval [CI]: 0.74 to 1.34) or major adverse cardiac events (MACE) (death, readmission for my

189 gender and sex with recurrent ACS and major adverse cardiac events (MACE) (e.g., ACS, cardiac mortal

190 onal primary PCI (18 trials, n=3,936): Major adverse cardiac events (MACE) (risk ratio [RR]: 0.76; 95

191 are and its associated 30-day rates of major adverse cardiac events (MACE) (the composite of cardiova

192 timing of surgery and stent type with major adverse cardiac events (MACE) adjusting for patient, sur

193 rdiac radiation dose is a predictor of major adverse cardiac events (MACE) and all-cause mortality (A

194 ended algorithm) for predicting 30-day major adverse cardiac events (MACE) and to compare it with the

195 Primary endpoint was major adverse cardiac events (MACE) at 1 year consisting of ca

196 imary effectiveness outcome was 2-year major adverse cardiac events (MACE) comprising death, readmiss

197 All patients were followed up for major adverse cardiac events (MACE) defined as a composite end

198 nd the combined endpoints (n = 116) of major adverse cardiac events (MACE) defined as cardiovascular

199 The primary outcome was major adverse cardiac events (MACE) defined by death, myocardi

200 with pneumococcal pneumonia experience major adverse cardiac events (MACE) during or after pneumonia.

201 by using cardiac MRI for prediction of major adverse cardiac events (MACE) following an acute ST-segm

202 However, the effects on mortality and major adverse cardiac events (MACE) have not been definitively

203 y and accurate detection of short-term major adverse cardiac events (MACE) in patients with suspected

204 great potential for the prediction of major adverse cardiac events (MACE) in ST-segment-elevation my

205 Major adverse cardiac events (MACE) included cardiac death, my

206 he primary endpoint was a composite of major adverse cardiac events (MACE) including cardiac death, n

207 ary microvascular dysfunction predicts major adverse cardiac events (MACE) independently of NAFLD.

208 year median follow-up, 136 (12%) first major adverse cardiac events (MACE) occurred (47 cardiovascula

209 etermine the annualized probability of major adverse cardiac events (MACE) of cardiac death or myocar

210 efficacy endpoint was the incidence of major adverse cardiac events (MACE) up to 30 days.

211 FFR for coronary revascularization and major adverse cardiac events (MACE) was assessed over a 1-year

212 Major adverse cardiac events (MACE) were assessed in the 2 pro

213 Major adverse cardiac events (MACE) were defined as a composit

214 Major adverse cardiac events (MACE) were defined as death, non

215 AF) with cardiovascular events (CVEs), major adverse cardiac events (MACE), and cardiovascular mortal

216 Major adverse cardiac events (MACE), comprising significant no

217 Primary endpoint was a composite of major adverse cardiac events (MACE), including cardiac death,

218 The primary end point was 1-year major adverse cardiac events (MACE), which included death/myoc

219 and nonfatal MI (death and/or MI), and major adverse cardiac events (MACE).

220 verolimus-eluting stents) for reducing major adverse cardiac events (MACE).

221 mportant risk factor for postoperative major adverse cardiac events (MACE).

222 ortality, cardiovascular mortality and major adverse cardiac events (MACE).

223 er such biomarkers stratified risks of major adverse cardiac events (MACE).

224 oints were in-stent binary restenosis, major adverse cardiac events (MACE: cardiac death, myocardial

225 Secondary end points were major adverse cardiac events (MACE; a composite of all-cause d

226 Secondary efficacy end points included major adverse cardiac events (MACE; cardiac death, myocardial

227 , target lesion revascularization, and major adverse cardiac events (MACE; death, myocardial infarcti

228 The incidence of major adverse cardiac events (MACE; the combined end point of

229 n (MI)/revascularization/stroke (i.e., major adverse cardiac events [MACE]) and secondary endpoints o

230 arction, and congestive heart failure (major adverse cardiac events [MACE]).

231 s associated with reduced incidence of major adverse cardiac events (MACEs) and cardiovascular (CV) r

232 The primary end points were major adverse cardiac events (MACEs) defined as cardiovascular

233 Evaluation for major adverse cardiac events (MACEs) occurred at 30 days (deat

234 Major adverse cardiac events (MACEs) were defined as late reva

235 according to their short-term risk for major adverse cardiac events (MACEs), but its effect on daily

236 Clinical outcomes in terms of major adverse cardiac events (major adverse cardiac events, a

237 he composite major adverse events (ie, major adverse cardiac events, major bleeding, or thromboemboli

238 The primary outcome was 30-day major adverse cardiac events (mortality, readmission for acute

239 nction (p < 0.001), increased risk for major adverse cardiac events, mutations in the tail of MYH7 (p

240 diovascular disease (CVD) and incident major adverse cardiac events (myocardial infarction, stroke or

241 Patients in whom major adverse cardiac events occurred had significantly larger

242 Major adverse cardiac events occurred in 1.1% and 4.2% of ever

243 Major adverse cardiac events occurred in 10.2% of patients in

244 Major adverse cardiac events occurred in 173 diabetics (14.5%)

245 After 5 years, major adverse cardiac events occurred in 31% of patients (154

246 Randomized lesion-related major adverse cardiac events occurred in 4.3% of BVS-treated p

247 0.76 to -0.21) and a decreased risk of major adverse cardiac events (odds ratio, 0.49; 95% CI, 0.25 t

248 ely followed up for 27+/-10 months for major adverse cardiac events of death, death or myocardial inf

249 rse cardiac or cerebrovascular events (major adverse cardiac event or ischemia-driven revascularizati

250 R, 5.34 [95% CI, 1.80-15.81] P=0.002), major adverse cardiac events (OR, 4.46 [95% CI, 1.70-11.70] P=

251 findings do not directly contribute to major adverse cardiac event outcomes.

252 rates of recurrent mitral regurgitation and adverse cardiac events over time.

253 death and heart failure (P=0.004) and major adverse cardiac events (P=0.013).

254 Overall, the 5-year major adverse cardiac event rate was 11.0%, without any scaffo

255 The 1-year adverse cardiac event rate was 16.4% in patients with in

256 m follow-up was 3.1 years, and overall major adverse cardiac event rate was 19.9% (death rate: 1.2%;

257 Two-year major adverse cardiac event rate was 6.8% without any scaffold

258 The 1-year major adverse cardiac event rate was increased among patients

259 The major adverse cardiac event rate was lower, too, in the allo g

260 ssociated with significantly increased major adverse cardiac events rate throughout 10 years of follo

261 6 hours, there was no change in 30-day major adverse cardiac event rates (0.52% versus 0.44%; P=0.96)

262 Major adverse cardiac event rates at 2 years among those witho

263 d significantly higher success but not major adverse cardiac event rates compared with inexperienced

264 higher in-hospital, 30-day, and 1-year major adverse cardiac event rates than patients without IPTE (

265 Major adverse cardiac event rates were similar (13.0% vs. 11.0

266 umen dimensions and low restenosis and major adverse cardiac event rates.

267 ith subsequent significantly increased major adverse cardiac event rates.

268 Target lesion revascularization and major adverse cardiac events rates during follow-up were highe

269 At 3 mo, 96 patients were free of major adverse cardiac events, repeat hospital chest pain evalu

270 nts were composite upper GI events and major adverse cardiac events, respectively.

271 posite end point of all-cause death or major adverse cardiac events: retransplantation, nonfatal myoc

272 o significant differences in composite major adverse cardiac event scores at each time point up to 48

273 h <50% diameter stenosis may carry a risk of adverse cardiac events similar to that in patients with

274 esel exhaust (DE) would increase the risk of adverse cardiac events such as arrhythmia and myocardial

275 sentation has an independent effect on major adverse cardiac events, suggesting that ISR remains a ha

276 eek mortality and 9-month incidence of major adverse cardiac events (the composite of death, Q-wave m

277 primary end point of this analysis was major adverse cardiac event, the composite of death, myocardia

278 5% CI, 1.19-1.73) all predicted MACEs [major adverse cardiac events]." These ORs and 95% CIs should h

279 Major adverse cardiac events through 12-month follow-up were a

280 h, AA and HL women have similar 1-year major adverse cardiac events to white women, although AA women

281 end points included clinical outcomes (major adverse cardiac events), use of healthcare resources, an

282 e index and a significant reduction in major adverse cardiac event was evident.

283 Overall occurrence of major adverse cardiac events was significantly less frequent i

284 The impact of ICR on major adverse cardiac events was similar regardless of chronic

285 spite treatment, the risk of long-term major adverse cardiac events was substantially increased in IE

286 ratios (95% confidence intervals) for major adverse cardiac events were 0.77 (0.68-0.87), 0.82 (0.73

287 Two-year major adverse cardiac events were 16.9% (retrospectively ident

288 The rates of major adverse cardiac events were 9.5% in hospitals without on

289 Adverse cardiac events were assessed as a composite end

290 08 as measured by the VerifyNow assay; major adverse cardiac events were defined as the composite of

291 ns, although significant reductions in major adverse cardiac events were present in all patient subgr

292 re-vascularized by CABG, mortality and major adverse cardiac events were significantly lower with a l

293 associated with lower risk for midterm major adverse cardiac events when used to supplement SITA or B

294 rate of nonfatal recurrent HF-related major adverse cardiac events while delaying or preventing prog

295 thrombosis, myocardial infarction, and major adverse cardiac events within 1 year after DES implantat

296 The primary end point was death or major adverse cardiac events within 1 year after surgery.

297 inical end point was the occurrence of major adverse cardiac events within 1 year.

298 5% confidence interval, 3.6%-9.5%) had major adverse cardiac events within 30 days of randomization.

299 nts identified for early discharge had major adverse cardiac events within 30 days.

300 (ZES 17.0% versus EES 16.2%, P=0.61), major adverse cardiac events (ZES 21.9% versus EES 21.6%, P=0.